DSIP vs Selank vs Semax: Research Comparison
DSIP, Selank, and Semax are often grouped together because they sit in the sleep, stress, and cognition research conversation. They should not be treated as the same category. DSIP is mainly discussed around sleep and neuroendocrine regulation. Selank is usually discussed around anxiety, stress, and immune-neuro signaling. Semax is usually discussed around cognition, neuroprotection, and neurotrophic signaling.
Compound-by-compound briefing
| Field | DSIP | Selank | Semax |
|---|---|---|---|
| Commonly researched for | Sleep architecture, delta-wave sleep, stress response, neuroendocrine regulation, and recovery rhythm research. | Stress response, anxiety-related research, emotional regulation, cognition, immune-neuro signaling, and resilience research. | Cognition, focus, neuroprotection, stroke-related research, BDNF-related signaling, and stress resilience. |
| Mechanism of interest | Not fully characterized. Studied for possible relationships with sleep-wake regulation, delta EEG patterns, stress signaling, and neuroendocrine modulation. | Studied as a synthetic peptide related to tuftsin analog research. Often discussed in relation to anxiolytic, stress-modulating, immune, and neurotransmitter-related pathways. | Studied as an ACTH fragment analog with possible neurotrophic, cognitive, and neuroprotective pathway interest. |
| Evidence strength | Limited | Limited to Early | Limited to Early |
| Human evidence | Limited and older. Small human studies exist, but the evidence is not strong enough to support broad insomnia or sleep treatment claims. | Limited by Western clinical standards. Some international research exists, but broad clinical claims require caution. | Limited by Western clinical standards. Some international clinical use and research exists, but not enough for broad claims in the United States. |
| Preclinical evidence | Early animal research contributed to the name delta sleep-inducing peptide, but the mechanism and reproducibility remain debated. | Supports interest in stress, anxiety, immune-neuro, and neurotransmitter-related mechanisms. | Supports interest in gene expression, neuroprotection, ischemia models, and neurotrophic signaling. |
| Main caution | Not FDA-approved as a sleep drug. FDA has flagged emideltide or DSIP in compounding-risk context due to safety-data limitations and peptide-related concerns. | Not FDA-approved. FDA has flagged selank acetate in compounding-risk context and notes limited safety-related information. | Not FDA-approved. FDA has flagged semax in compounding-risk context and notes limited safety-related information. |
| Regulatory status | Not FDA-approved for general clinical use. | Not FDA-approved for general clinical use. | Not FDA-approved for general clinical use. |
- Commonly researched for
- Sleep architecture, delta-wave sleep, stress response, neuroendocrine regulation, and recovery rhythm research.
- Mechanism of interest
- Not fully characterized. Studied for possible relationships with sleep-wake regulation, delta EEG patterns, stress signaling, and neuroendocrine modulation.
- Evidence strength
- Limited
- Human evidence
- Limited and older. Small human studies exist, but the evidence is not strong enough to support broad insomnia or sleep treatment claims.
- Preclinical evidence
- Early animal research contributed to the name delta sleep-inducing peptide, but the mechanism and reproducibility remain debated.
- Main caution
- Not FDA-approved as a sleep drug. FDA has flagged emideltide or DSIP in compounding-risk context due to safety-data limitations and peptide-related concerns.
- Regulatory status
- Not FDA-approved for general clinical use.
- Commonly researched for
- Stress response, anxiety-related research, emotional regulation, cognition, immune-neuro signaling, and resilience research.
- Mechanism of interest
- Studied as a synthetic peptide related to tuftsin analog research. Often discussed in relation to anxiolytic, stress-modulating, immune, and neurotransmitter-related pathways.
- Evidence strength
- Limited to Early
- Human evidence
- Limited by Western clinical standards. Some international research exists, but broad clinical claims require caution.
- Preclinical evidence
- Supports interest in stress, anxiety, immune-neuro, and neurotransmitter-related mechanisms.
- Main caution
- Not FDA-approved. FDA has flagged selank acetate in compounding-risk context and notes limited safety-related information.
- Regulatory status
- Not FDA-approved for general clinical use.
- Commonly researched for
- Cognition, focus, neuroprotection, stroke-related research, BDNF-related signaling, and stress resilience.
- Mechanism of interest
- Studied as an ACTH fragment analog with possible neurotrophic, cognitive, and neuroprotective pathway interest.
- Evidence strength
- Limited to Early
- Human evidence
- Limited by Western clinical standards. Some international clinical use and research exists, but not enough for broad claims in the United States.
- Preclinical evidence
- Supports interest in gene expression, neuroprotection, ischemia models, and neurotrophic signaling.
- Main caution
- Not FDA-approved. FDA has flagged semax in compounding-risk context and notes limited safety-related information.
- Regulatory status
- Not FDA-approved for general clinical use.
Comparing Compounds? Read This First.
The Playbook helps you understand evidence quality, mechanism claims, safety limitations, and sourcing red flags before comparing research compounds.
Educational research only. No medical advice, dosing instructions, treatment recommendations, or personalized healthcare guidance.
Plain-language difference
DSIP belongs mostly to the sleep conversation. Selank belongs mostly to the stress and anxiety-modulation conversation. Semax belongs mostly to the cognition and neuroprotection conversation. They overlap in the nervous system, but they should not be presented as interchangeable nootropics.
Mechanism comparison
DSIP is the least mechanistically settled and is tied to sleep architecture and neuroendocrine discussion. Selank is often discussed around stress response, anxiolytic-like signaling, and immune-neuro modulation. Semax is more commonly tied to neuroprotection, cognition, and neurotrophic signaling. The clean distinction is sleep rhythm, stress regulation, and cognitive-neuroprotective research.
Evidence comparison
All three require conservative evidence grading. DSIP has small and older human studies with mixed or limited support. Selank and Semax have international research histories, but they lack the kind of large, FDA-reviewed clinical evidence that would support broad medical claims in the United States. The right framing is research interest, not proven treatment.
Safety and regulatory context
None of these should be marketed as approved treatments for insomnia, anxiety, depression, ADHD, brain injury, stroke, or cognitive decline. Research-use-only products raise quality concerns, especially around sterility, purity, identity, and labeling. Because these compounds affect nervous system research pathways, unsupported claims should be avoided.
Continue down a research path
Full compound breakdowns
Research-Use-Only Sourcing Standards
Before evaluating any supplier, review the standards that matter: Certificate of Analysis access, batch transparency, purity testing, clear labeling, restrained claims, and research-use-only positioning.
- 01Certificate of Analysis available
- 02Batch or lot transparency
- 03Purity testing clearly stated
- 04Clear compound labeling
- 05No exaggerated medical claims
- 06Research-use-only language
- 07Supplier disclosure visible
Some supplier links may be affiliate links. Peptide Pressure may earn compensation. Affiliate relationships do not influence evidence grading, safety framing, or editorial standards.
Disclaimer: This page is for educational and research purposes only. It does not provide medical advice, dosing instructions, treatment recommendations, or personalized healthcare guidance.